- Record: found
- Abstract: not found
- Article: not found
Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients
December 2018
December 2018
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
There is a need for efficacious and safe pain treatments for OA (osteoarthritis).
The nerve growth factor (NGF) antibody tanezumab is associated with high efficacy,
but when combined with chronic NSAID treatment shows an increased risk of rapidly
progressive osteoarthritis (RPOA) in a small group of patients.